Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
暂无分享,去创建一个
Marco Boscaro | A. Colao | M. Boscaro | B. Biller | Annamaria Colao | S. Petersenn | V. Bonert | Stephan Petersenn | Beverly MK Biller | Vivien S Bonert | Beverly M. K. Biller | Vivien S. Bonert
[1] S. Melmed,et al. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. , 2002, Nature medicine.
[2] Susan M. Brown,et al. BROMOCRIPTINE SUPPRESSES ACTH SECRETION FROM HUMAN PITUITARY TUMOUR CELLS IN CULTURE BY A DOPAMINERGIC MECHANISM , 1981, Clinical endocrinology.
[3] F. Di Salle,et al. Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly , 2002, Clinical endocrinology.
[4] P. Cappabianca,et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. , 2000, The Journal of clinical endocrinology and metabolism.
[5] S. Melmed,et al. New developments in the management of acromegaly , 1997 .
[6] P. Wrightson,et al. Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.
[7] D. Nelson,et al. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. , 1960, Annals of internal medicine.
[8] A. Khandji,et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. , 2000, The Journal of clinical endocrinology and metabolism.
[9] P. Freda,et al. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.
[10] C. Szmigielski,et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma , 2009, Clinical endocrinology.
[11] M. Omura,et al. [Medical treatment for Cushing's syndrome]. , 2008, Nihon rinsho. Japanese journal of clinical medicine.
[12] A. Colao,et al. Growth-hormone and prolactin excess , 1998, The Lancet.
[13] M. Nasrallah,et al. Pituitary tumors: pathophysiology, clinical manifestations and management. , 2001, Endocrine-Related Cancer.
[14] L. Niskanen,et al. A nationwide survey of mortality in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.
[15] J. Wardlaw,et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly , 2007, Clinical endocrinology.
[16] R. Murray,et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. , 2004, The Journal of clinical investigation.
[17] F. Trimarchi,et al. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline , 1999, Journal of endocrinological investigation.
[18] Y. Wang,et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. , 2009, The Journal of clinical endocrinology and metabolism.
[19] P. Cappabianca,et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. , 2009, The Journal of clinical endocrinology and metabolism.
[20] K. Schmid,et al. Differential Expression of the Human Somatostatin Receptor Subtypes sst1 to sst5 in Various Adrenal Tumors and Normal Adrenal Gland , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[21] A. Grossman,et al. Short and long‐term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome , 1991, Clinical endocrinology.
[22] J. Bertherat,et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. , 2007, The Journal of clinical endocrinology and metabolism.
[23] S. Dagogo-Jack,et al. Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. , 1993, The American journal of medicine.
[24] M. Boscaro,et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. , 1996, The Journal of clinical endocrinology and metabolism.
[25] M. Laudat,et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. , 1979, The New England journal of medicine.
[26] M. Molitch. Dopamine Resistance of Prolactinomas , 2004, Pituitary.
[27] N. Christy. Choosing the best treatment for acromegaly. , 1982, Journal of the American Medical Association (JAMA).
[28] Elena S. Di Martino,et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies , 2008, Journal of endocrinological investigation.
[29] J. Régis,et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. , 2007, European journal of endocrinology.
[30] M. Thorner,et al. Treatment of prolactinomas. , 1983, Surgical neurology.
[31] J. Romijn,et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. , 2009, The Journal of clinical endocrinology and metabolism.
[32] A. Rigby,et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. , 2008, European journal of endocrinology.
[33] R. McNally,et al. Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .
[34] J. Bevan. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.
[35] P. Chanson,et al. Consensus statement: medical management of acromegaly. , 2005, European journal of endocrinology.
[36] S. Melmed. Acromegaly and cancer: not a problem? , 2001, The Journal of clinical endocrinology and metabolism.
[37] J. Kros,et al. Dopamine receptor expression and function in corticotroph pituitary tumors. , 2004, The Journal of clinical endocrinology and metabolism.
[38] A. Colao,et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. , 2007, European journal of endocrinology.
[39] P. Chanson,et al. Merits and pitfalls of mifepristone in Cushing's syndrome. , 2009, European journal of endocrinology.
[40] D. Schteingart,et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. , 1980, Annals of internal medicine.
[41] H. Lochs,et al. [Prevalence of diabetes in acromegaly and Cushing syndrome]. , 2000, Acta medica Austriaca.
[42] E. Arvat,et al. Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease , 2006, Clinical endocrinology.
[43] L. Nieman,et al. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. , 2001, The Journal of clinical endocrinology and metabolism.
[44] S. Lamberts,et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. , 2004, The Journal of clinical endocrinology and metabolism.
[45] J. Schlechte,et al. Management of resistant prolactinomas , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[46] H. Schmid. Pasireotide (SOM230): Development, mechanism of action and potential applications , 2008, Molecular and Cellular Endocrinology.
[47] J. Taylor,et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. , 2005, European journal of endocrinology.
[48] P. Stewart,et al. Efficacy of Sandostatin® LAR® (long‐acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy , 2004, Clinical endocrinology.
[49] A. J. van der Lely,et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.
[50] S. Lamberts,et al. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients , 2005, Clinical endocrinology.
[51] Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.
[52] P. Cappabianca,et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.
[53] R. Reznek,et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. , 1998, The Journal of clinical endocrinology and metabolism.
[54] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[55] A. Colao,et al. Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.
[56] J. Schlechte. Long-term management of prolactinomas. , 2007, The Journal of clinical endocrinology and metabolism.
[57] F. Holsboer,et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. , 2006, Endocrinology.
[58] M. Bronstein,et al. Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institution , 2005, Clinical endocrinology.
[59] G. Meno-Tetang,et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.
[60] F. Trimarchi,et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. , 2004, European journal of endocrinology.
[61] J. A. Scarlett,et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.
[62] M. Galderisi,et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. , 2009, The Journal of clinical endocrinology and metabolism.
[63] S. Ezzat,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY , 2004 .
[64] Jeroen J. Bax,et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.
[65] L. Pierard,et al. Cabergoline and the risk of valvular lesions in endocrine disease. , 2008, European journal of endocrinology.
[66] P. Freda. Somatostatin analogs in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.
[67] H. Lochs,et al. Diabetes‐Häufigkeit bei Akromegalie und Cushing‐Syndrom , 2000 .
[68] E. Menis,et al. First‐line octreotide‐LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial , 2006, Clinical endocrinology.
[69] H. Schmid,et al. Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors , 2004, Neuroendocrinology.
[70] S. Lamberts,et al. The pathophysiological consequences of somatostatin receptor internalization and resistance. , 2003, Endocrine reviews.
[71] S. Orme,et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. , 1998, The Journal of clinical endocrinology and metabolism.
[72] H. Raff,et al. Cushing's Syndrome: important issues in diagnosis and management. , 2006, The Journal of clinical endocrinology and metabolism.
[73] B. Ambrosi,et al. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion , 1990, Journal of endocrinological investigation.
[74] D. McCance,et al. Long‐term remission rates after pituitary surgery for Cushing's disease: the need for long‐term surveillance , 2005, Clinical endocrinology.
[75] J. Taylor,et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. , 2005, Journal of endocrinological investigation.
[76] P. Cappabianca,et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. , 2004, The New England journal of medicine.
[77] R. Clayton. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? , 1997, The Journal of endocrinology.
[78] D. Torigian,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Octreotide as Primary Therapy for Acromegaly* , 2022 .
[79] J. Janssen,et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly , 2005, The Lancet.
[80] P. Freda. Pegvisomant therapy for acromegaly , 2006, Expert review of endocrinology & metabolism.
[81] D. Rabinowitz,et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.
[82] Shereen Ezzat,et al. The prevalence of pituitary adenomas , 2004, Cancer.
[83] P. Laurberg,et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.
[84] S. Melmed. Medical progress: Acromegaly. , 2006, The New England journal of medicine.
[85] M. Korbonits,et al. PPAR‐γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti‐proliferative effect of the glitazones is independent of the PPAR‐γ receptor , 2006, Clinical endocrinology.
[86] A. Beckers,et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. , 1998, The Journal of clinical endocrinology and metabolism.
[87] N. Pouratian,et al. GAMMA KNIFE RADIOSURGERY FOR ACROMEGALY: OUTCOMES AFTER FAILED TRANSSPHENOIDAL SURGERY , 2008, Neurosurgery.
[88] C. Invitti,et al. TREATMENT OF CUSHING'S SYNDROME WITH THE LONG‐ACTING SOMATOSTATIN ANALOGUE SMS 201‐995 (SANDOSTATIN) , 1990, Clinical endocrinology.
[89] S. Savastano,et al. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. , 2008, The Journal of clinical endocrinology and metabolism.
[90] P. Cooper,et al. Treatment of Cushing's disease with o,p'-DDD. , 1979, The New England journal of medicine.
[91] W. Ludlam. Gamma Knife Radiosurgery for Acromegaly: Outcomes after Failed Transsphenoidal Surgery , 2009 .
[92] J. Petit,et al. Proton stereotactic radiosurgery in management of persistent acromegaly. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[93] S. Lamberts,et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. , 2005, European journal of endocrinology.
[94] A. Antonini,et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.
[95] J. Bertherat,et al. Treatment of ACTH-dependent Cushing ’ s syndrome : a consensus statement , 2008 .
[96] S. Lamberts,et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[97] A B Atkinson,et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. , 2003, The Journal of clinical endocrinology and metabolism.
[98] G. Gamble,et al. Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.
[99] L. Nieman,et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. , 2008, The Journal of clinical endocrinology and metabolism.
[100] Y. Patel. Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.
[101] S. Melmed,et al. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. , 2007, Endocrinology.
[102] G. Lasio,et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status , 2004, Clinical endocrinology.
[103] S. Melmed,et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. , 2010, The Journal of clinical endocrinology and metabolism.
[104] R. Weiss,et al. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. , 2005, The Journal of clinical endocrinology and metabolism.
[105] A. Klibanski,et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study , 2010, Clinical endocrinology.
[106] J. Webster. A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation , 1996 .
[107] D. Hoyer,et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. , 2005, American journal of physiology. Endocrinology and metabolism.
[108] N. Oyesiku. Stereotactic radiosurgery for Cushing disease: a review. , 2007, Neurosurgical focus.
[109] P. Cappabianca,et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre study , 2009, Clinical endocrinology.
[110] S. Melmed,et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. , 2008, The Journal of clinical endocrinology and metabolism.
[111] I. Lancranjan,et al. Dopamine D2 receptor gene expression in human adenohypophysial adenomas , 2001, Endocrine.
[112] C. Stratakis,et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.
[113] R. Fahlbusch,et al. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.
[114] K. Takano,et al. Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. , 2005, Endocrine journal.
[115] S. Melmed. CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem? , 2001 .
[116] P. Orlandi,et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? , 1998, European journal of endocrinology.
[117] G. Lasio,et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. , 2006, The Journal of clinical endocrinology and metabolism.
[118] X. Badia,et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.
[119] S. Ezzat,et al. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[120] M. Carson,et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. , 2006, The Journal of clinical endocrinology and metabolism.
[121] C. Brain,et al. Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing’s Disease , 2005, Hormone Research in Paediatrics.
[122] H. Schulte,et al. Genomic structure and transcriptional regulation of the human somatostatin receptor type 2 , 1999, Molecular and Cellular Endocrinology.
[123] M. S. Tewart,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .
[124] S. Melmed,et al. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas , 2002, Nature Medicine.
[125] P. Schoeffter,et al. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. , 2005, European journal of endocrinology.
[126] A. Schatzberg,et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). , 2001, The Journal of clinical endocrinology and metabolism.
[127] A. Beckers,et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.
[128] I. Morange,et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. , 2008, European journal of endocrinology.
[129] E. Motti,et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. , 2003, Journal of Clinical Endocrinology and Metabolism.
[130] B. Byrd,et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[131] P. Cappabianca,et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. , 2001, The Journal of clinical endocrinology and metabolism.
[132] K. Serri,et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas , 2008, Pituitary.
[133] M. Culler,et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. , 2008, European journal of endocrinology.
[134] J. A. Scarlett,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.
[135] GAMMA KNIFE RADIOSURGERY FOR ACROMEGALY: OUTCOMES AFTER FAILED TRANSSPHENOIDAL SURGERY , 2008 .
[136] M. Molitch,et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. , 1985, The Journal of clinical endocrinology and metabolism.
[137] F. Bogazzi,et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia , 2008, International journal of clinical practice.